Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
暂无分享,去创建一个
A. Poprach | B. Melichar | T. Buchler | O. Fiala | K. Kopečková | J. Finek | T. Doležal | L. Capkova | M. Zemanova | J. Kopecký | T. Mlcoch | T. Mlčoch | K. Kopeckova